Meta Platforms delivered a positive earnings reaction on May 27. The PCR just made a new year-to-date low. The two facts are not unrelated.
The put/call ratio closed Thursday at 0.4528 — the lowest reading of 2026 and a fresh extension below the prior 52-week low of 0.4588 flagged in the last note. It sits 2.4 standard deviations below the 20-day mean of 0.484. The drift has been steady: from 0.50 in early May, through 0.47 after earnings, and now to 0.45. Traders are not hedging — they are pressing calls into the next event.
That next event is July 22 earnings. The last two earnings have produced moves of +3.7% and -8.9% respectively. The options market is currently positioned as if the upside scenario is the base case.
Short interest rose to 1.47% of free float as of May 28 — up 10.2% over the week and 21.3% over the month. In absolute terms, roughly 32 million shares are short. That is not a threatening level, but the directional trend is worth watching. Some traders are leaning against the post-earnings bounce.
Cost to borrow sits at 0.42%, up roughly 49% over the past month from levels near 0.28%. The borrow market remains exceptionally loose — availability is deep with ample supply. The CTB move reflects incremental demand for borrows, not any squeeze dynamic.
Following the April earnings miss, a wave of target cuts arrived. JP Morgan downgraded to Neutral and cut to $725. Wells Fargo trimmed to $765. Mizuho, Stifel, and TD Cowen all lowered targets. Rosenblatt maintained its $1,015 Buy this week.
The consensus remains firmly Buy. The mean target stands at $826 against a current price of $635. That implies 30% upside — wide enough to keep institutional buyers engaged even after the target trims.
Capital Research added 6.7 million shares in the most recent filing period. JP Morgan Asset Management added 4 million. T. Rowe Price added 4.3 million. The buyers are not small names.
See the live data behind this article on ORTEX.
Open META on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.